The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study

被引:0
作者
Kim, Seong-Kyu [1 ,2 ]
Kim, Ji-Won [1 ]
Lee, Hwajeong [1 ]
Park, Sung-Hoon [1 ]
Choe, Jung-Yoon [1 ]
Kim, Boyoung [1 ]
机构
[1] Catholic Univ Daegu, Dept Internal Med, Div Rheumatol, Sch Med, Daegu, South Korea
[2] Catholic Univ Daegu, Dept Internal Med, Div Rheumatol, Sch Med, 33 Duryugongwon Ro 17 Gil, Daegu 42472, South Korea
关键词
bisphosphonate; BMD; denosumab; osteoporosis; SERMs; OSTEOCLAST DIFFERENTIATION; TURNOVER MARKERS; DOUBLE-BLIND; DIAGNOSIS; METHOTREXATE; MULTICENTER; RECEPTOR; COLLEGE; EROSION; LIGAND;
D O I
10.1097/MD.0000000000034219
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Little is known about differences in the therapeutic efficacy of denosumab in subjects with and without rheumatoid arthritis (RA). This study compares the changes in bone mineral density (BMD) between RA patients and controls without RA who had been treated with denosumab for 2 years for postmenopausal osteoporosis. A total of 82 RA patients and 64 controls were enrolled, who were refractory to selective estrogen receptor modulators (SERMs) or bisphosphonates and completed the treatment of denosumab 60 mg for 2 years. The efficacy of denosumab in RA patients and controls was assessed using areal BMD (aBMD) and T-score of the lumbar spine, femur neck, and total hip. A general linear model with repeated measures analysis of variance was used to determine differences in aBMD and T-score between 2 study groups. No significant differences in percent changes in aBMD and T-scores by denosumab treatment for 2 years at the lumbar spine, femur neck, and total hip were evident between RA patients and controls (P > .05 of all), except T-score of the total hip (P = .034). Denosumab treatment equally increased aBMD at the lumbar spine and T-scores at the lumbar spine and total hip between RA patients and controls without statistical differences, but RA patients showed less improvement in aBMD at the femur neck (p(time*group) = 0.032) and T-scores at the femur neck and total hip than controls (p(time*group) = 0.004 of both). Changes in aBMD and T-scores after denosumab treatment in RA patients were not affected by previous use of bisphosphonates or SERMs. Differences of T-score at the femur neck among previous bisphosphonate users and aBMD and T-score at the femur neck and T-scores at the total hip were evident. This study revealed that 2 years of denosumab treatment in female RA patients achieved comparable efficacy on BMD to controls at the lumbar spine, but showed somewhat insufficient improvement at the femur neck and total hip.
引用
收藏
页数:9
相关论文
共 35 条
[11]   Rapid and Sustained Improvement in Bone and Cartilage Turnover Markers With the Anti-Interleukin-6 Receptor Inhibitor Tocilizumab Plus Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Results From a Substudy of the Multicenter Double-Blind, Placebo-Controlled Trial of Tocilizumab in Inadequate Responders to Methotrexate Alone [J].
Garnero, Patrick ;
Thompson, Elizabeth ;
Woodworth, Thasia ;
Smolen, Josef S. .
ARTHRITIS AND RHEUMATISM, 2010, 62 (01) :33-43
[12]   Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease [J].
Greenblatt, Matthew B. ;
Tsai, Joy N. ;
Wein, Marc N. .
CLINICAL CHEMISTRY, 2017, 63 (02) :464-474
[13]   Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis [J].
Gulyas, Katalin ;
Horvath, Agnes ;
Vegh, Edit ;
Pusztai, Anita ;
Szentpetery, Agnes ;
Petho, Zsofia ;
Vancsa, Andrea ;
Bodnar, Nora ;
Csomor, Peter ;
Hamar, Attila ;
Bodoki, Levente ;
Bhattoa, Harjit Pal ;
Juhasz, Balazs ;
Nagy, Zoltan ;
Hodosi, Katalin ;
Karosi, Tamas ;
FitzGerald, Oliver ;
Szucs, Gabriella ;
Szekanecz, Zoltan ;
Szamosi, Szilvia ;
Szanto, Sandor .
CLINICAL RHEUMATOLOGY, 2020, 39 (01) :167-175
[14]   Standardization of femur BMD [J].
Hanson, J .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (08) :1316-1317
[15]   The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data [J].
Hu, Qiongwen ;
Zhong, Xue ;
Tian, Hua ;
Liao, Pu .
FRONTIERS IN IMMUNOLOGY, 2022, 12
[16]   Prevalence and risk factors for bone loss in rheumatoid arthritis patients from South China: modeled by three methods [J].
Hu, Zhuoran ;
Zhang, Lei ;
Lin, Zhiming ;
Zhao, Changlin ;
Xu, Shuiming ;
Lin, He ;
Zhang, Jiejing ;
Li, Wenjie ;
Chu, Yongliang .
BMC MUSCULOSKELETAL DISORDERS, 2021, 22 (01)
[17]   Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT [J].
Jin, Shangyi ;
Li, Mengtao ;
Wang, Qian ;
Zeng, Xiaofeng ;
Xia, Weibo ;
Yu, Wei ;
Guan, Wenmin ;
Hsieh, Evelyn .
ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
[18]   Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates [J].
Kaneko, Tetsuya ;
Okamura, Koichi ;
Yonemoto, Yukio ;
Okura, Chisa ;
Suto, Takahito ;
Tachibana, Masahiro ;
Sakane, Hideo ;
Inoue, Makoto ;
Chikuda, Hirotaka .
JOURNAL OF EXPERIMENTAL ORTHOPAEDICS, 2019, 6 (01)
[19]   An update on the diagnosis and assessment of osteoporosis with densitometry [J].
Kanis, JA ;
Glüer, CC .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (03) :192-202
[20]   Diagnosis of osteoporosis and assessment of fracture risk [J].
Kanis, JA .
LANCET, 2002, 359 (9321) :1929-1936